The functions and regulation of the PTEN tumour suppressor
By M. Song, L. Salmena, P. Pandolfi. Nature reviews. Molecular cell biology, 2012
2,025 citations recorded by the source corpus.
Subfields: Cancer Research, Molecular Biology, Oncology
View Paper: https://www.semanticscholar.org/paper/39d0e12b6cf87cc58c7520da6194e2c3371c260b
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cancer Research
- Matthew Meyerson
- Gad Getz
- M. Lawrence
- Christopher Sander
- Peter W. Laird
- Fazlul H. Sarkar
- Gautam Sethi
- Charles M. Perou
In Molecular Biology
- Ryuji Hamamoto
- Yusuke Nakamura
- Takehiro Suzuki
- N. Dohmae
- Makoto Nakakido
- Jay Shendure
- Zhenzhong Deng
- Hui Shen
In Oncology
- William E. Evans
- John N. Weinstein
- Christopher Sander
- Nikolaus Schultz
- Peter W. Laird
- Fazlul H. Sarkar
- Charles M. Perou
- Gad Getz
Citations in the corpus
- Comprehensive molecular portraits of invasive lobular breast cancer (2015, background): “Consistent with PTEN function as a negative regulator of Akt activity (Cantley and Neel, 1999; Song et al., 2012), ILC tumors also showed significantly increased Akt phosphorylation at both S473 (p = 0.004) and T308 (p = 7E-5) (Figure 4A).”
- Phosphoinositides: tiny lipids with giant impact on cell regulation. (2013, background): “PTEN 15.”
- Exosomes in Cancer Development, Metastasis and Drug Resistance: A Comprehensive Review (2013, positive): “Phosphatase and tensin homolog (PTEN) is a protein that, in humans, is encoded by the PTEN gene and acts as a tumor suppressor [94].”
- Dysregulation of AKT Pathway by SMYD2-Mediated Lysine Methylation on PTEN (2015, background): “Phosphatase and tensin homologue (PTEN) was originally identified to be frequently disrupted inmultiple sporadic tumor types and targeted by germline mutations in patients with cancer predisposition syndromes like Cowden disease [1,2].”
- PI3K/Akt/mTOR Pathway and Its Role in Cancer Therapeutics: Are We Making Headway? (2022, background): “Furthermore, PTEN deficiency may also result in increased genomic instability, allowing for the accumulation of deleterious mutations (43).”
- PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer (2023, background): “PTEN loss frequently occurs in primary and metastatic breast cancer leading to hyperactivation of PAM pathway, and consequently, enhancing cell proliferation [89, 90].”
- Multiplex Assessment of Protein Variant Abundance by Massively Parallel Sequencing (2018, background): “PTEN mediates the removal of the 3 ′ phosphate from phosphatidylinositol 3,4,5-triphosphate (PIP 3 ) to produce phosphatidylinositol 4,5-diphosphate (PIP 2 ) at the membrane 28 .”